Metrics as of 10/16/2026, 06:59 AM (Berlin time), refresh in progress.
Dr. Reddy's Laboratories Stock
Dr. Reddy's Laboratories Limited
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- India
- CEO
- Erez Israeli
- Employees
- 27,527
- Market cap
- $10.7 B
- IPO
- 11/04/2001
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and…
Dr. Reddy's Laboratories stock: price history
1D
+1.2%
1W
+5.7%
1M
+11.7%
6M
-1.2%
YTD
-8.1%
1Y
-8.3%
2Y
-18.5%
5Y
-2.3%
10Y
+43.2%
Next earnings date
Next earnings date
23/10/2026 (in 6 days)
Volatility around earnings
~31% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Dr. Reddy's Laboratories stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 20/08/2026.
Ask the agents about Dr. Reddy's Laboratories
Analyst assessment of Dr. Reddy's Laboratories
PRICE TARGET LOW
US$14.80
CONSENSUS
US$14.80
MEDIAN
US$14.80
PRICE TARGET HIGH
US$14.80
0
STRONG BUY
6
BUY
4
HOLD
2
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 29/09/2026
Dr. Reddy's Laboratories stock metrics
P/E
30.87
P/B
2.66
EV/EBITDA
16.23
RETURN ON EQUITY
1.2%
NET MARGIN
5.5%
DEBT/EQUITY
0.19
DIVIDEND YIELD
0.7%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
100.0%
FLOAT SHARES
832,674,592
AVG. DAILY VOLUME (30D)
3,187,725
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +1.2%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Dr. Reddy's Laboratories stock
What does Dr. Reddy's Laboratories do?
Dr. Reddy's Laboratories Limited is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in India.
The CEO is Erez Israeli, the company employs around 27,527 people.
The IPO was on 11/04/2001; the stock trades on NYSE under the ticker RDY.
What do analysts say about Dr. Reddy's Laboratories stock?
12 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$14.80, ranging from US$14.80 to US$14.80, with a median of US$14.80.
This is an external assessment, not a statement by Market Jury.
When does Dr. Reddy's Laboratories report next?
The next earnings date is 23/10/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does Dr. Reddy's Laboratories pay a dividend?
Yes. The last dividend was US$0.08 per share, ex-date 24/07/2026, paid on 05/08/2026.
The dividend yield is 0.7% (as of 30/06/2026).
Which stocks are comparable to Dr. Reddy's Laboratories?
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get Dr. Reddy's Laboratories stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dr. Reddy's Laboratories against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.